Chord Therapeutics is a pharmaceutical corporation in the clinical stage of drug development
Chord Therapeutics is a pharmaceutical corporation in the clinical stage of drug development. They specialize in creating medications for patients with rare and severe illnesses that can be life-threatening or cause significant disability. The company's primary focus is on advancing their lead drug candidate, CRD1, which has been granted orphan drug status for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and myasthenia gravis (MG).